Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Alpha Teknova, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
SC 13G/A
| Telegraph Hill Partners IV, L.P. reports a 62.9% stake in Alpha Teknova, Inc. |
| 09/27/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Teknova Reports Second Quarter 2023 Financial Results Second quarter 2023 total revenue was $11.5 million, up 26% sequentially Received certification of new state-of-the-art facility for production of GMP-grade products Company revises 2023 revenue guidance to $37-40 million, continues to anticipate free cash outflows of $30 million for full year HOLLISTER, Calif., August 10, 2023 – Alpha Teknova, Inc. , a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2023. “Today we reported strong operating results for the second quarter of 2023, increasing revenue sequentially by 26%, despite a challenging market environment..." |
|
| 07/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/15/2023 |
8-K
| Quarterly results|
Docs:
|
"Teknova Reports Fourth Quarter and Full Year 2022 Financial Results Full year 2022 total revenue was $41.4 million, up 12% year-over-year New, state-of-the-art manufacturing facility now operational Company provides 2023 revenue guidance of $42-46 million HOLLISTER, Calif., March 15, 2023 – Alpha Teknova, Inc. , a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and the full year ended December 31, 2022. “We achieved our operational objectives in 2022, positioning the company for significant and sustainable long-term growth,” said Stephen Gunstream, President and Chief Executive Officer of Teknova. “Despi..." |
|
| 01/30/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 11/09/2022 |
8-K
| Quarterly results|
Docs:
|
"Teknova Reports Third Quarter 2022 Financial Results Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year Company updates 2022 revenue outlook to $40-42 million Cash position of $50 million supports path to profitability HOLLISTER, Calif., November 9, 2022 – Alpha Teknova, Inc. , a leading provider of critical reagents for the discovery, research, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2022. “Teknova delivered a solid third quarter revenue performance, driven by robust Lab Essentials growth and healthy demand across our broad customer base,” said Stephen Gunstream, President and CEO of Teknova. “Most recently, we ent..." |
|
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Teknova Reports Second Quarter 2022 Financial Results Second quarter 2022 total revenue was $11.7 million, up 41% year-over-year Cash position of $64.7 million supports ongoing investment in growth strategy Company updates 2022 revenue outlook to $38-42 million HOLLISTER, Calif., August 10, 2022 – Alpha Teknova, Inc. , a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2022. “We were pleased with our second quarter revenue growth and the excellent progress on the build-out of our new manufacturing facility,” said Stephen Gunstream, President and CEO of Teknova. “While we continue to see healthy ..." |
|
| 07/13/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/01/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/11/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 03/18/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/15/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2022 |
SC 13G
| Davis Ted reports a 12.8% stake in ALPHA TEKNOVA, INC. |
| 01/27/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 11/15/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Offer Letter, between Alpha Teknova, Inc. and Ken Gelhaus",
"Teknova Expands Leadership Team with the Appointments of Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as Senior Vice President, Marketing HOLLISTER, Calif., Nov 10, 2021 - Alpha Teknova, Inc. , a leading manufacturer of cell culture media and supplements, protein purification buffers, and molecular biology reagents, today announced the appointments of Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as Senior Vice President, Marketing. “We're truly excited that Ken and Jennifer have chosen to join our leadership team,” said Stephen Gunstream, CEO of Teknova. “Both of them bring uniquely valuable experience to their roles,” he continued. “Ken knows how to build and lead successful commercial organizations in complex life sciences businesses. That's what we've challen..." |
|
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/10/2021 |
8-K
| Quarterly results |
| 08/13/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 08/11/2021 |
8-K
| Quarterly results |
| 06/29/2021 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 06/29/2021 |
8-K
| Quarterly results |
| 06/25/2021 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
|
|
|